Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.76 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.76 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.76 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.76 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.76 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.76 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.76 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.76 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.76 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.76 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.76 |
| ▸ | PRNP | P04156 | 1/20 | 0.76 |
| ▸ | APP | P05067 | 1/20 | 0.76 |
| ▸ | NQO2 | P16083 | 1/20 | 0.76 |
| ▸ | MTOR | P42345 | 1/20 | 0.76 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL709359 | 0.94 | CHRM2 (0.80) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| SCHEMBL21158517 | 0.87 | CHRM2 (0.78) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| SCHEMBL15481297 | 0.87 | CHRM2 (0.78) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Chloroquine SCHEMBL27814047 | 0.87 | CHRM2 (0.96) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Chloroquine SCHEMBL8933 | 0.86 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| SCHEMBL15483240 | 0.86 | CHRM2 (0.76) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Chloroquine SCHEMBL8474661 | 0.86 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| SCHEMBL29523096 | 0.86 | CHRM2 (0.76) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| (R)-Chloroquine SCHEMBL134500 | 0.86 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Chloroquine SCHEMBL8934 | 0.86 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000893-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | UNIV EMORY (US) | 2023-01-05 | — | — | US | claimed |
| EP-1581167-A4 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS | ALPHA RES GROUP LLC (US) | 2008-10-29 | — | — | EP | claimed |
| JP-2006514917-A | — | — | 2006-05-18 | — | — | JP | claimed |
| EP-1581167-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS | Alpha Research Group, LLC (US) | 2005-10-05 | — | — | EP | claimed |
| EP-1261340-A4 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | ALPHA RES GROUP LLC (US) | 2005-05-04 | — | — | EP | claimed |
| US-20040229908-A1 | Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias | Greenlee, Winner and Sullivan, P.C. | 2004-11-18 | — | — | US | claimed |
| WO-2004004660-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON’S DISEASE AND TARDIVE DYSKINESIAS | ALPHA RESEARCH GROUP, L.L.C. (US) | 2004-01-15 | — | — | WO | claimed |
| JP-2004500331-A | — | — | 2004-01-08 | — | — | JP | claimed |
| US-20020198231-A1 | Compositions and methods for the treatment of Parkinson's disease | Greenlee, Winner and Sullivan, P.C. | 2002-12-26 | — | — | US | claimed |
| EP-1261340-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | Alpha Research Group, LLC (US) | 2002-12-04 | — | — | EP | claimed |
| WO-2001003649-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | ALPHA RESEARCH GROUP, LLC (US) | 2001-01-18 | — | — | WO | claimed |
| US-20240228646-A9 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF | AVIDITY BIOSCIENCES INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240216414-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | UNIV EMORY (US) | 2024-07-04 | — | — | US | disclosed |
| US-12006499-B2 | Una amidites and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-11999955-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| WO-2004004660-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON’S DISEASE AND TARDIVE DYSKINESIAS | ALPHA RESEARCH GROUP, L.L.C. (US) | 2004-01-15 | — | — | WO | disclosed |
| US-20020198231-A1 | Compositions and methods for the treatment of Parkinson's disease | Greenlee, Winner and Sullivan, P.C. | 2002-12-26 | — | — | US | disclosed |
| EP-1261340-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | Alpha Research Group, LLC (US) | 2002-12-04 | — | — | EP | disclosed |
| US-6417177-B1 | Chloroquine derivatives for the treatment of Parkinson's disease | ALPHA RESEARCH GROUP, LLC | 2002-07-09 | — | — | US | disclosed |
| WO-2001003649-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | ALPHA RESEARCH GROUP, LLC (US) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000893-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | SAMHD1, PNP, NUDT1 | CHRM2 3532/4885CHRM4 2569/4885CHRM5 1846/4885 |
| US-12006499-B2 | Una amidites and uses thereof | NCL, PNP, NASP | CHRM2 2890/4885CHRM4 3546/4885CHRM5 3030/4885 |
| US-20240228646-A9 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF | TFRC, FOLR1, CD47 | CHRM2 4057/4885CHRM4 4342/4885CHRM5 3910/4885 |
| US-11999955-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | MTPN, MYOF, CPT1B | CHRM2 3455/4885CHRM4 3472/4885CHRM5 3450/4885 |
| US-20240216414-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | SAMHD1, PNP, NUDT1 | CHRM2 3532/4885CHRM4 2569/4885CHRM5 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.